The effect of N-acetylcysteine on the incidence of contrast-induced kidney injury: A systematic review and trial sequential analysis

International Journal of Cardiology

Volumn 209, Issue , 2016, Pages 319-327

  Wang, Nelson ^a   Qian, Pierre ^b   Kumar, Shejil ^c   Yan, Tristan D ^a   Phan, Kevin ^a,b  

^a MACQUARIE UNIVERSITY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Acute kidney injury; Angioplasty; Contrast; Meta analysis; Percutaneous coronary intervention; Trial sequential analysis

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; SCAVENGER;

ACUTE CORONARY SYNDROME; AGE; ANGIOCARDIOGRAPHY; ARTICLE; COHORT ANALYSIS; CONTRAST INDUCED NEPHROPATHY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; INCIDENCE; KIDNEY FAILURE; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RISK FACTOR; RISK REDUCTION; SEQUENTIAL ANALYSIS; SYSTEMATIC REVIEW; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; META ANALYSIS; PROCEDURES; TREATMENT OUTCOME;

ACETYLCYSTEINE; ACUTE KIDNEY INJURY; CONTRAST MEDIA; FREE RADICAL SCAVENGERS; HUMANS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84961683854     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.02.083     Document Type: Article

References (66)

1. M. Al-Ghonaim, and N. Pannu Prevention and treatment of contrast-induced nephropathy Tech. Vasc. Interv. Radiol. 9 2 Jun 2006 42 49
2. K. Nash, A. Hafeez, and S. Hou Hospital-acquired renal insufficiency Am.J. Kidney Diseases 39 5 May 2002 930 936
3. P.A. McCullough, R. Wolyn, L.L. Rocher, R.N. Levin, and W.W. O'Neill Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality Am. J. Med. 103 5 Nov 1997 368 375
4. C. Mueller, G. Buerkle, H.J. Buettner, and et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty Arch. Intern. Med. 162 3 Feb 11 2002 329 336
5. M.Y. Wu, H.F. Hsiang, C.S. Wong, and et al. The effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials Int. Urol. Nephrol. 45 5 Oct 2013 1309 1318
6. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT) Circulation 124 11 Sep 13 2011 1250 1259
7. C. Briguori, A. Colombo, A. Violante, and et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity Eur. Heart J. 25 3 Feb 2004 206 211
8. Davidson CJ, M. Hlatky, Morris KG, and et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial Ann. Intern. Med. 110 2 Jan 15 1989 119 124
9. S.K. Morcos Contrast-induced nephropathy: are there differences between low osmolar and iso-osmolar iodinated contrast media? Clin. Radiol. 64 5 May 2009 468 472
10. C.S. Baker, A. Wragg, S. Kumar, R. De Palma, L.R. Baker, and C.J. Knight A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study J. Am. Coll. Cardiol. 41 12 Jun 18 2003 2114 2118
11. P.A. McCullough, A. Adam, C.R. Becker, and et al. Risk prediction of contrast-induced nephropathy Am. J. Cardiol. 98 6a Sep 18 2006 27 k 36 k
12. M.J. Schweiger, C.E. Chambers, C.J. Davidson, and et al. Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures Catheter. Cardiovasc. Interv. 69 1 Jan 2007 135 140
13. T. Senoo, M. Motohiro, H. Kamihata, and et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome Am. J. Cardiol. 105 5 Mar 1 2010 624 628
14. R.M. Turner, S.M. Bird, and J.P. Higgins The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews PLoS One 8 3 2013 e59202
15. J. Wetterslev, K. Thorlund, J. Brok, and C. Gluud Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis J. Clin. Epidemiol. 61 1 Jan 2008 64 75
16. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann. Intern. Med. 151 4 2009 264 269
17. M. Agrawal, A.M. Wodlinger, C.E. Huggins, and et al. Effect of N-acetylcysteine on serum creatinine concentration in patients with chronic renal insufficiency who are undergoing coronary angiography Heart Drug 4 2 2004 87 91
18. M.A. Albabtain, A. Almasood, H. Alshurafah, H. Alamri, and H. Tamim Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-induced nephropathy: a prospective randomized study J. Interv. Cardiol. 26 1 Feb 2013 90 96
19. S. Allaqaband, R. Tumuluri, A.M. Malik, and et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy Catheter. Cardiovasc. Interv. 57 3 Nov 2002 279 283
20. M. Amini, M. Salarifar, A. Amirbaigloo, F. Masoudkabir, and F. Esfahani N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial Trials 10 2009 45
21. E. Aslanger, B. Uslu, C. Akdeniz, N. Polat, Y. Cizgici, and H. Oflaz Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty Coron. Artery Dis. 23 4 Jun 2012 265 270
22. A. Awal, S.A. Ahsan, M.A. Siddique, and et al. Effect of hydration with or without N-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention Mymensingh Med. J. 20 2 Apr 2011 264 269
23. A.D. Azmus, C. Gottschall, A. Manica, and et al. Effectiveness of acetylcysteine in prevention of contrast nephropathy J. Invasive Cardiol. 17 2 Feb 2005 80 84
24. D.C. Balderramo, M.B. Verdu, C.F. Ramacciotti, and et al. Renoprotective effect of high periprocedural doses of oral N-acetylcysteine in patients scheduled to undergo a same-day angiography Rev. Fac. Cienc. Med. (Cordoba, Argentina) 61 2 2004 13 19
25. M. Baskurt, B. Okcun, O. Abaci, and et al. N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy Eur. J. Clin. Investig. 39 9 Sep 2009 793 799
26. C. Briguori, F. Manganelli, P. Scarpato, and et al. Acetylcysteine and contrast agent-associated nephrotoxicity J. Am. Coll. Cardiol. 40 2 Jul 17 2002 298 303
27. M. Brueck, H. Cengiz, R. Hoeltgen, and et al. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial J. Invasive Cardiol. 25 6 Jun 2013 276 283
28. N. Carbonell, M. Blasco, R. Sanjuan, and et al. Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial Int. J. Cardiol. 115 1 Jan 31 2007 57 62
29. L.C. Coyle, A. Rodriguez, R.E. Jeschke, A. Simon-Lee, K.C. Abbott, and A.J. Taylor Acetylcysteine in diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics Am. Heart J. 151 5 May 2006 (1032.e1039-1012)
30. L.J. Diaz-Sandoval, B.D. Kosowsky, and D.W. Losordo Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial) Am. J. Cardiol. 89 3 Feb 1 2002 356 358
31. J.D. Durham, C. Caputo, J. Dokko, and et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography Kidney Int. 62 6 Dec 2002 2202 2207
32. J.W. Fung, C.C. Szeto, W.W. Chan, and et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial Am. J. Kidney Dis. 43 5 May 2004 801 808
33. I. Goldenberg, M. Shechter, S. Matetzky, and et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature Eur. Heart J. 25 3 Feb 2004 212 218
34. V.O. Gomes, Poli de Figueredo CE, P. Caramori, and et al. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial Heart (British Cardiac Society) 91 6 Jun 2005 774 778
35. O. Gulel, T. Keles, H. Eraslan, S. Aydogdu, E. Diker, and V. Ulusoy Prophylactic acetylcysteine usage for prevention of contrast nephropathy after coronary angiography J. Cardiovasc. Pharmacol. 46 4 Oct 2005 464 467
36. Z. Jaffery, A. Verma, C.J. White, and et al. A randomized trial of intravenous N-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes Catheter. Cardiovasc. Interv. 79 6 May 1 2012 921 926
37. J. Kay, W.H. Chow, T.M. Chan, and et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial JAMA 289 5 Feb 5 2003 553 558
38. J.M. Kefer, C.E. Hanet, S. Boitte, L. Wilmotte, and M. De Kock Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient? Acta Cardiol. 58 6 Dec 2003 555 560
39. T. Kinbara, T. Hayano, N. Ohtani, Y. Furutani, K. Moritani, and M. Matsuzaki Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy J. Cardiol. 55 2 Mar 2010 174 179
40. F. Koc, K. Ozdemir, M.G. Kaya, and et al. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS - a multicenter prospective controlled trial Int. J. Cardiol. 155 3 Mar 22 2012 418 423
41. E. Kotlyar, A.M. Keogh, S. Thavapalachandran, and et al. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures - a randomised controlled trial Heart Lung Circ. 14 4 Dec 2005 245 251
42. B.D. MacNeill, S.A. Harding, H. Bazari, and et al. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography Catheter. Cardiovasc. Interv. 60 4 Dec 2003 458 461
43. G. Marenzi, E. Assanelli, I. Marana, and et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty N. Engl. J. Med. 354 26 Jun 29 2006 2773 2782
44. S.E. Miner, V. Dzavik, P. Nguyen-Ho, and et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up Am. Heart J. 148 4 Oct 2004 690 695
45. A. Ochoa, G. Pellizzon, S. Addala, and et al. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention J. Interv. Cardiol. 17 3 Jun 2004 159 165
46. J.B. Oldemeyer, W.P. Biddle, R.L. Wurdeman, A.N. Mooss, E. Cichowski, and D.E. Hilleman Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography Am. Heart J. 146 6 Dec 2003 E23
47. E.E. Ozcan, S. Guneri, B. Akdeniz, and et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial Am. Heart J. 154 3 Sep 2007 539 544
48. J.A. Ratcliffe, P. Thiagarajah, J. Chen, and et al. Prevention of contrast-induced nephropathy: a randomized controlled trial of sodium bicarbonate and N-acetylcysteine Int. J. Angiol. 18 4 Winter 2009 193 197
49. H. Reinecke, M. Fobker, J. Wellmann, and et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the dialysis-versus-diuresis (DVD) trial Clin. Res. Cardiol. 96 3 Mar 2007 130 139
50. R.A. Seyon, L.A. Jensen, I.A. Ferguson, and R.G. Williams Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention Heart Lung 36 3 May-Jun 2007 195 204
51. K.G. Shyu, J.J. Cheng, and P. Kuan Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure J. Am. Coll. Cardiol. 40 8 Oct 16 2002 1383 1388
52. A. Tanaka, Y. Suzuki, N. Suzuki, and et al. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction? Intern. Med. (Tokyo, Japan) 50 7 2011 673 677
53. P. Thayssen, J.F. Lassen, S.E. Jensen, and et al. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial Circ. Cardiovasc. Interv. 7 2 Apr 2014 216 224
54. H. Thiele, L. Hildebrand, C. Schirdewahn, and et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (prospective, single-blind, placebo-controlled, randomized Leipzig immediate percutaneous coronary intervention acute myocardial infarction N-ACC) trial J. Am. Coll. Cardiol. 55 20 May 18 2010 2201 2209
55. Z.D. Wan Mohd Izani Wan Mohamed, and Zurkurnai Yusof Oral N-acetylcysteine in prevention of contrast induced nephropathy following coronary angiogram Intern. Med. J. 15 5 2008 353 361
56. J.G. Webb, G.E. Pate, K.H. Humphries, and et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect Am. Heart J. 148 3 Sep 2004 422 429
57. K. Yang, W. Liu, W. Ren, and S. Lv Different interventions in preventing contrast-induced nephropathy after percutaneous coronary intervention Int. Urol. Nephrol. 46 9 Sep 2014 1801 1807
58. M.R. Yeganehkhah, L. Iranirad, F. Dorri, and et al. Comparison between three supportive treatments for prevention of contrast-induced nephropathy in high-risk patients undergoing coronary angiography Saudi J. Kidney Dis. Transpl. 25 6 Nov 2014 1217 1223
59. M. Maeder, M. Klein, T. Fehr, and H. Rickli Contrast nephropathy: review focusing on prevention J. Am. Coll. Cardiol. 44 9 Nov 2 2004 1763 1771
60. R.S. Loomba, P.H. Shah, S. Aggarwal, and R.R. Arora Role of N-acetylcysteine to prevent contrast-induced nephropathy: a meta-analysis Am. J. Ther. 23 1 2016 e172 e183
61. R. Mehran, and E. Nikolsky Contrast-induced nephropathy: definition, epidemiology, and patients at risk Kidney Int. Suppl. 100 Apr 2006 S11 S15
62. C.S. Rihal, S.C. Textor, D.E. Grill, and et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention Circulation 105 19 May 14 2002 2259 2264
63. C.L. Tommaso Contrast-induced nephrotoxicity in patients undergoing cardiac catheterization Catheter. Cardiovasc. Diagn. 31 4 Apr 1994 316 321
64. P.A. Poletti, P. Saudan, A. Platon, and et al. I.V. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity AJR Am. J. Roentgenol. 189 3 Sep 2007 687 692
65. S.J. Shalansky, T. Vu, G.E. Pate, A. Levin, K.H. Humphries, and J.G. Webb N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best? Pharmacotherapy 25 8 Aug 2005 1095 1103
66. Z. Sun, Q. Fu, L. Cao, W. Jin, L. Cheng, and Z. Li Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials PLoS One 8 1 2013 e55124